Paris, France, September 24, 2024 – Coave Therapeutics, a pioneering force in genetic medicine focused on advancing treatments for eye and neurodegenerative disorders, is set to reveal groundbreaking data concerning its innovative peptide-conjugated vector technology. This exciting development is a pivotal element of the company’s ALIGATER™ (Advanced Vectors-Ligand Conjugates) platform, which promises to transform gene therapy delivery methods.

This state-of-the-art technology enables the precise targeting of adeno-associated virus (AAV) and lipid nanoparticle (LNP) vectors to specific cellular receptors. More importantly, it enhances the affinity between the vectors and their targets, offering a superior solution for the tailored delivery of genetic medicines.

Coave's CEO, Rodolphe Clerval, will share insights regarding the company's advancements at two important investor conferences: - Chardan’s 8th Annual Genetic Medicines Conference: September 30 – October 1, New York City, NY, USA. Clerval will present on September 30 at 13:30 EDT. - Jefferies London Healthcare Conference: November 19-21, London, UK. Clerval will be available for investor meetings.

In addition to investor-focused discussions, Coave will present novel scientific findings from its ALIGATER™ platform at the European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress from October 22-25 in Rome, Italy. The poster presentation, titled "The Advanced Ligand Conjugation (ALIGATER™) platform chemically redirects AAV and LNP vectors towards specific receptors via peptide-mediated targeting," will occur on October 23 from 13:30-15:00 CEST (Poster ID# P0074).

Why This Matters: Coave Therapeutics stands at the forefront of a revolution in genetic medicine. With its proprietary ALIGATER™ platform, the company is not only targeting rare diseases but also addressing more prevalent conditions, like various forms of neurodegeneration and ocular diseases. Their research has demonstrated the ability of conjugated vectors to achieve enhanced biodistribution in the central nervous system and the eye, showing promise in treating both genetically defined and non-genetically defined disorders.

Based in Paris, Coave Therapeutics is supported by prominent investors in the life sciences sector. For more details about their innovative science and pipeline developments, visit their official website.

Stay tuned as Coave Therapeutics prepares to unveil data that could redefine the future of gene therapy!